PubMed Daily Triage Digest — 2026-07-29

Run: attempt1 · 20260729T090000Z
Date window: CRDT 2026-07-28 → 2026-07-29
Topics scanned: 10 (9 watchlist + sentinel)
Candidates reviewed: 115 total (T1:15 T2:3 T3:15 T4:15 T5:15 T6:15 T7:15 T8:2 T9:15 Sentinel:10)
Articles selected: 20 (HIGH: 14 · STANDARD: 6 · LOW: 0)

🔴 HIGH Priority (14 articles)

Hematologic Malignancies (5 HIGH)

[TRANSCEND CLL 004 — Primary Results] PMID 42520199 · Score 9/10
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda WG, Dorritie KA, Gauthier J, … Siddiqi T
Blood · 2026-07-28 · DOI: 10.1182/blood.2026033565
🔬 Phase 2 trial · Human · Subscription

Key finding: Liso-cel + ibrutinib combination achieved high response rates with manageable toxicity in relapsed/refractory CLL/SLL, supporting CAR-T + BTK inhibitor as a new therapeutic paradigm.
Why it matters: Landmark primary results from a multicenter Phase 2 trial of CAR-T + BTKi in R/R CLL/SLL published in Blood — the leading hematology journal. Directly actionable for CLL management after BTKi/BCL-2 failure; potential practice-changing implications for this high-unmet-need population.

[ALL Immunology — Cell Reports Medicine] PMID 42520804 · Score 8/10
Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia
Kumar A, Hamane K, Duault C, … Swaminathan S
Cell Rep Med · 2026-07-28 · DOI: 10.1016/j.xcrm.2026.102945
🔬 Translational multi-cohort · Mixed (murine + human) · Subscription

Key finding: Tumor-induced DC dysfunction suppresses T cell proliferation in ALL and correlates with inferior clinical outcomes, identifying DC deregulation as a targetable immune evasion mechanism.
Why it matters: High-impact Cell Reports Medicine paper advancing ALL immunobiology. Novel immune evasion axis with direct therapeutic targeting implications; supports DC restoration strategies for immunotherapy combination in ALL.

[Dupilumab Lymphoma Safety] PMID 42521147 · Score 7/10
Risk of Lymphoma in Patients with Asthma Treated with Dupilumab Compared with Other Biologic Agents: A Retrospective Cohort Study
Liao KM, Huang SC, Kuo CY, … Lai CC
Chest · 2026-07-28 · DOI: 10.1016/j.chest.2026.07.5213
🔬 Retrospective cohort · Human · Subscription

Key finding: Dupilumab-treated asthma patients did not have significantly elevated lymphoma risk vs other biologic agents; pharmacovigilance safety reassurance for this widely-prescribed IL-4/IL-13 antagonist.
Why it matters: Important safety data for the millions on dupilumab (atopic dermatitis, asthma). Large Chest cohort study addressing the lymphoma safety signal; relevant to hematologic malignancy safety monitoring in dermatology/pulmonology patients.

[ALK+ T-Cell Lymphoma — Blood] PMID 42520200 · Score 7/10
CD4+ T cells orchestrate the immune response to ALK-positive T-cell lymphoma
Poggio T, Gräßel L, Andrieux G, … Illert AL
Blood · 2026-07-28 · DOI: 10.1182/blood.2026033240
🔬 Translational mechanistic · Mixed · Subscription

Key finding: CD4+ T cells are essential immune orchestrators in ALK+ T-cell lymphoma; CD4+ depletion worsens outcomes in preclinical models while CD4+ infiltration correlates with patient prognosis.
Why it matters: Blood publication revealing a novel immune axis in ALK+ ALCL — a rare but challenging lymphoma subtype. Mechanistic rationale for CD4+ T cell-augmenting immunotherapy; potential therapeutic target in ALK-positive ALCL.

[Belantamab Mafodotin — Dose Optimization Review] PMID 42521571 · Score 7/10
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
Mina R, Terpos E, Cani L, … Lonial S
Clin Lymphoma Myeloma Leuk · 2026-06-25 (indexed 2026-07-28) · DOI: 10.1016/j.clml.2026.06.014
🔬 Review · Human · Subscription

Key finding: Practical dose optimization and ophthalmic monitoring strategies for belantamab mafodotin can maintain MM anti-tumor efficacy while substantially reducing BCMA-ADC corneal toxicity.
Why it matters: Expert practice guide for the key toxicity management challenge limiting adoption of this FDA-approved BCMA-directed ADC for R/R MM. Directly actionable for MM clinicians managing belantamab-treated patients.

CBC / ML Hematology (1 HIGH)

[CBC Cancer Pre-Staging — 24 Months] PMID 42520469 · Score 8/10
Haematological pre-staging of colorectal cancer: Longitudinal trends identify high-risk metastatic phenotypes 24 months prior to diagnosis
Sala RJ, Ery J, Cuesta-Peredo D, Muedra V, Rodilla V
Transl Oncol · 2026-07-28 · DOI: 10.1016/j.tranon.2026.102954
🔬 Retrospective longitudinal cohort · Human · Subscription

Key finding: Routine CBC parameters exhibit distinctive longitudinal trend signatures identifying high-risk colorectal cancer metastatic phenotypes up to 24 months before clinical diagnosis.
Why it matters: First demonstration of CBC temporal trends predicting CRC 24 months before diagnosis — a paradigm-shifting finding for the CBC/ML hematology watchlist. If externally validated, could enable routine blood-based pre-screening algorithms for CRC risk stratification.

Early Cancer Detection / Liquid Biopsy (1 HIGH)

[ctMoniTR — ctDNA Across 10 RCTs] PMID 42519677 · Score 8/10
Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project
Andrews HS, Zariffa N, Goren EM, … Allen JD (Friends of Cancer Research / cross-industry consortium)
J Liq Biopsy · 2026-07-15 (indexed 2026-07-28) · DOI: 10.1016/j.jlb.2026.100481 · PMC13382393
🔬 Patient-level meta-analysis of 10 RCTs · Human · Open Access

Key finding: Early ctDNA decreases (≥90% reduction: aHR OS 0.51; clearance: aHR OS 0.45) were significantly associated with improved OS and PFS across 10 RCTs; trial-level surrogate validity stronger for PFS than OS, particularly in advanced NSCLC (R² up to 0.74).
Why it matters: First cross-industry patient-level meta-analysis (10 RCTs, AstraZeneca/Novartis/Pfizer/Genentech/Guardant/Foundation Medicine/Natera/Biodesix/Boehringer Ingelheim/Merck KGaA) assessing ctDNA as a regulatory surrogate endpoint across cancer types. Directly informs FDA/EMA biomarker validation strategy for ctDNA-based endpoints in clinical trials.

AI / ML in Clinical Diagnostics (2 HIGH)

[Breathomics Lung Cancer — 5,214 Patients] PMID 42521150 · Score 8/10
Development and Multi-center Validation of a Breathomics-Based Triage Tool for Lung Cancer: A Prospective Study of 5,214 Participants
Qin J, Sun M, Li X, … Sun D
Chest · 2026-07-28 · DOI: 10.1016/j.chest.2026.06.067
🔬 Prospective multicenter diagnostic accuracy study · Human · Subscription

Key finding: ML breathomics model (exhaled VOCs + clinical factors) achieved AUC 0.85 in independent external validation (n=545), with 93.1% sensitivity and 71.0% NPV — the largest prospective breath test validation for lung cancer triage to date.
Why it matters: Largest prospective multicenter breathomics validation study (n=5,214); AUC 0.85 with geographically independent prospective cohort. Published in Chest. Addresses a key clinical gap: non-invasive triage of CT-detected pulmonary abnormalities to reduce unnecessary biopsies. High translational readiness.

[ML Cardiac irAE Prediction — ICI Patients] PMID 42521802 · Score 7/10
Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors
Sayer M, Chang PD, Hamano H, … Ozaki AF
Support Care Cancer · 2026-07-29 · DOI: 10.1007/s00520-026-10984-5
🔬 Retrospective database ML study (n=61,117) · Human · Open Access

Key finding: ML models (gradient boosting, random forest, elastic net) trained on 61,117 ICI-treated patients predicted cardiac irAEs (AUC 0.71–0.72) and effectively stratified patients into low/medium/high-risk tiers with significantly different event rates.
Why it matters: Large-scale (n=61,117) ML risk stratification for cardiac irAEs — rare but potentially fatal complications of ICI therapy. Open access publication; practical risk stratification framework applicable to cardio-oncology monitoring programs. AUC modest but clinically meaningful for rare event prediction.

Precision Oncology / Genomics (1 HIGH)

[Hereditary Cancer + Precision Oncology — EJHG Review] PMID 42521810 · Score 7/10
Bridging the gap: integrating hereditary cancer into precision oncology
Rezqallah A, Cruellas M, Balmaña J (Vall d'Hebron / Lozano Blesa)
Eur J Hum Genet · 2026-07-28 · DOI: 10.1038/s41431-026-02196-6
🔬 Narrative review · Human · Subscription

Key finding: Germline alterations in BRCA1/2, MMR genes, VHL, RET, and NF1 define immediately actionable precision therapy targets — PARP inhibitors, ICB, HIF2α inhibitors, selective RET kinase inhibitors, and RAS pathway inhibitors — supporting expanded germline testing beyond traditional family history criteria.
Why it matters: Comprehensive clinical framework for precision therapeutics in hereditary cancer syndromes (∼10% of all cancers) from Nature Publishing Group journal. Covers multiple FDA-approved targeted therapies; actionable summary for expanding germline testing programs in oncology.

Cardiovascular-Metabolic / GLP-1 / SGLT2 (2 HIGH)

[SGLT2i in Older Adults — Landmark Cohort] PMID 42521604 · Score 8/10
Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study
Noma H, Yamazaki H, Sunada H, Oda F, Maeda M, Fukuda H
Diabetes Obes Metab · 2026-07-28 · DOI: 10.1111/dom.71151
🔬 Nationwide landmark cohort (n=24,380, IPTW) · Human · Subscription

Key finding: Sustained SGLT2i use (≥6 months) was associated with lower heart failure hospitalization (HR 0.775) and MACE (HR 0.848) in older adults with T2DM vs DPP-4i; HF benefit consistent across BMI strata; BMI-related MACE heterogeneity requires further study.
Why it matters: Large nationwide cohort (n=24,380) specifically addressing SGLT2i effectiveness in older adults — a population underrepresented in pivotal RCTs. Consistent heart failure benefit across BMI strata strengthens generalizability. Immediately practice-informing for the large geriatric cardiometabolic population.

[GLP-1 RA + Skin Cancer Safety — Target Trial Emulation] PMID 42521622 · Score 7/10
GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation
Tang H, Zhang B, Lu Y, … Chen Y (University of Pennsylvania CHASE)
Diabetes Obes Metab · 2026-07-28 · DOI: 10.1111/dom.71142
🔬 Target trial emulation (n=235,797 matched pairs) · Human · Open Access

Key finding: GLP-1 RA initiation was not associated with increased melanoma risk; borderline NMSC increase vs SGLT2i (HR 1.06) was attenuated after negative-control outcome calibration — overall supporting GLP-1 RA cancer safety profile.
Why it matters: Well-powered target trial emulation (235,797 pairs) providing cancer safety pharmacovigilance data for GLP-1 RAs prescribed to tens of millions. Null/reassuring result for melanoma; borderline NMSC signal largely confounded. Open access; important for the growing cardiometabolic-oncology safety monitoring space.

🟡 STANDARD Priority (6 articles)

Note (42521819): Nature Medicine perspective/commentary. No abstract indexed in PubMed at time of run (title-only record). Conservative cap applied per schema rules; scored STANDARD despite Nature Medicine venue. Key policy framing for rare disease diagnosis reform — recommend follow-up fetch when full text available.

Coverage Notes

Generated by Friday (OpenClaw) · PubMed E-utilities · api_key:2b9c5a25ba8ac7a28d425063730a43719608 · Attempt 1 of 3